Lexicon Pharma (LXRX) Tops Q3 EPS by 14c
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Third Quarter Financial Results
November 1, 2016 7:00 AM EDTTHE WOODLANDS, Texas, Nov. 1, 2016 /PRNewswire/ --Â Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the third quarter ended September 30, 2016 and provided an overview of key milestones for the company's lead drug candidates.
"We achieved a key milestone in the third quarter with the release of positive top-line results from our first pivotal Phase 3 clinical trial of sotagliflozin in patients with type 1 diabetes, followed by favorable results in October from a Phase 2 study that supported our Phase... More
Lexicon Announces Publication Of TELESTAR Study Results For Telotristat Ethyl In The Journal Of Clinical Oncology
October 31, 2016 4:30 PM EDTTHE WOODLANDS, Texas, Oct. 31, 2016 /PRNewswire/ --Â Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that the Journal of Clinical Oncology published detailed results from Lexicon's pivotal Phase 3 TELESTAR clinical study of telotristat... More